Side effects of Effexor

The short version: Effexor works for depression and anxiety, but the side effect burden is real and dose-dependent, and the evidence base is almost entirely manufacturer-funded.

The evidence here comes from Wyeth-Ayerst, the manufacturer, who paid for the main depression trial [1] and the generalized anxiety trial [3]. That is a structural conflict. A manufacturer-funded trial is marketing with a Methods section until independent replication shows otherwise. The GAD trial [3] gives the clearest picture of side effects across doses. At 75 mg daily, nausea hit 43% of patients versus 12% on placebo. Dry mouth was 20% versus 6%. Insomnia 17% versus 14%. Dizziness 19% versus 11%. At 225 mg, those numbers climbed: nausea 47%, dry mouth 30%, insomnia 31%, dizziness 26%. About 29% of patients dropped out overall, and more dropped from the drug groups than from placebo [3]. That is not a trivial signal.

The breast cancer hot flash trials [2, 4] add a useful cross-check because they were not funded by Wyeth. In one, venlafaxine 75 mg caused nausea in about 20% of patients and led to more early dropouts than clonidine [2]. In the other, the 75 mg and 150 mg groups both showed increased mouth dryness, decreased appetite, nausea, and constipation [4]. The 150 mg group had the worst tolerability. The pattern is consistent: nausea, dry mouth, insomnia, dizziness, and appetite loss are real and dose-related.

The open-label ADHD study in children [5] reported similar rates: nausea 32%, headache 32%, stomach ache 24%, drowsiness 24%, restlessness 24%, poor appetite 18%, insomnia 18%. That is a short two-week pilot, not a long-term safety trial, but the pattern holds even in kids.

Two rare but serious risks appear in case reports. Serotonin syndrome can occur when venlafaxine is combined with other serotonergic drugs like risperidone [7]. One elderly patient on venlafaxine plus risperidone developed definite serotonin syndrome and recovered after stopping both drugs [7]. Another case report describes neuroleptic malignant syndrome in a young woman on venlafaxine plus four other psychiatric drugs [6]. These are single cases, not population rates, but the mechanism is plausible: venlafaxine raises serotonin and norepinephrine, and stacking drugs that do the same can push the system over the edge.

The CYP2D6 genotype matters. Poor metabolizers have higher venlafaxine concentrations and lower concentrations of its active metabolite [8]. That means the same dose can produce very different blood levels in different people. If you are a poor metabolizer, you may get a stronger effect and more side effects from a standard dose. Most prescribers do not check this.

My call: Effexor works for depression and anxiety, but the side effects are common, dose-dependent, and the evidence base is manufacturer-funded. The nausea, insomnia, and sexual side effects are real. Serotonin syndrome is rare but real when combined with other drugs. The dose should start low and go slow, and CYP2D6 testing would be rational but is almost never done. Confidence: moderate.